Investigational magnetic device shrinks glioblastoma in human test


Date:
July 22, 2021
Source:
Houston Methodist
Summary:
Researchers shrunk a deadly glioblastoma tumor by more than a third
using a helmet generating a noninvasive oscillating magnetic field
that the patient wore on his head while administering the therapy
in his own home.

The 53-year-old patient died from an unrelated injury about a
month into the treatment, but during that short time, 31% of the
tumor mass disappeared. The autopsy of his brain confirmed the
rapid response to the treatment.



FULL STORY ========================================================================== Houston Methodist Neurological Institute researchers from the department
of neurosurgery shrunk a deadly glioblastoma tumor by more than a third
using a helmet generating a noninvasive oscillating magnetic field that
the patient wore on his head while administering the therapy in his own
home. The 53-year- old patient died from an unrelated injury about a
month into the treatment, but during that short time, 31% of the tumor
mass disappeared. The autopsy of his brain confirmed the rapid response
to the treatment.


========================================================================== "Thanks to the courage of this patient and his family, we were able to
test and verify the potential effectiveness of the first noninvasive
therapy for glioblastoma in the world," said David S. Baskin, M.D.,
FACS, FAANS, corresponding author and director of the Kenneth R. Peak
Center for Brain and Pituitary Tumor Treatment in the Department of Neurosurgery at Houston Methodist. "The family's generous agreement to
allow an autopsy after their loved ones' untimely death made an invaluable contribution to the further study and development of this potentially
powerful therapy." In a case study published in Frontiers in Oncology
Baskin and his colleagues detailed the journey of their pioneering patient
who suffered from end-stage recurrent glioblastoma, despite a radical
surgical excision, chemoradiotherapy and experimental gene therapy.

Glioblastoma is the deadliest of brain cancers in adults, nearly always
fatal, with a life expectancy of a few months to two years. When the
patient's glioblastoma recurred in August 2019, Baskin and his team,
already working on the OMF treatment in mouse models, received FDA
approval for compassionate use treatment of the patient with their newly invented Oncomagnetic Device under an Expanded Access Program (EAP). The protocol also was approved by the Houston Methodist Research Institute Institutional Review Board.

The treatment consisted of intermittent application of an oscillating
magnetic field generated by rotating permanent magnets in a specific
frequency profile and timing pattern. First administered for two hours
under supervision in the Peak Clinic, ensuing treatments were given at
home with help from the patient's wife, with increasing treatment times
up to a maximum of only six hours per day.

The Oncomagnetic Device looks deceptively simple: three oncoscillators
securely attached to a helmet and connected to a microprocessor-based electronic controller operated by a rechargeable battery, an invention
by case study co- author Dr. Santosh Helekar. During the patient's five
weeks of treatment, the magnetic therapy was well-tolerated and the tumor
mass and volume shrunk by nearly a third, with shrinkage appearing to
correlate with the treatment dose.

The ongoing research is supported by the Translational Research Initiative
of the Houston Methodist Research Institute, Donna and Kenneth Peak,
the Kenneth R. Peak Foundation, the John S. Dunn Foundation, the Taub Foundation, the Blanche Green Fund of the Pauline Sterne Wolff Memorial Foundation, the Kelly Kicking Center Foundation, the Gary and Marlee Swarz Foundation, the Methodist Hospital Foundation and the Veralan Foundation.

"Imagine treating brain cancer without radiation therapy or
chemotherapy," said Baskin. "Our results in the laboratory and with
this patient open a new world of non-invasive and nontoxic therapy
for brain cancer, with many exciting possibilities for the future." ========================================================================== Story Source: Materials provided by Houston_Methodist. Note: Content
may be edited for style and length.


========================================================================== Journal Reference:
1. David S. Baskin, Martyn A. Sharpe, Lisa Nguyen, Santosh
A. Helekar. Case
Report: End-Stage Recurrent Glioblastoma Treated With a New
Noninvasive Non-Contact Oncomagnetic Device. Frontiers in Oncology,
2021; 11 DOI: 10.3389/fonc.2021.708017 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2021/07/210722163000.htm

--- up 10 weeks, 6 days, 22 hours, 45 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1337:3/111)